MO35-3 Comparison of clinical outcomes between 1st-line osimertinib, 1G/2G EGFR-TKIs followed by osimertinib and without osimertinib

Yuji Uehara,Tatsuya Yoshida,Yuki Takeyasu,Akiko Tateichi,Masahiro Torasawa,Ken Masuda,Yuki Shinno,Yuji Matsumoto,Yusuke Okuma,Yasushi Goto,Hidehito Horinouchi,Noboru Yamamoto,Yuichiro Ohe

Annals of Oncology（2023）

引用 0|浏览1

暂无评分

摘要

FLAURA trial showed that first-line Osimertinib (Osi) prolonged OS compared with first-generation (1G) EGFR-TKIs in EGFR-mutant NSCLC. Treatment sequencing with Osi after 1G/2G EGFR-TKIs could prolong survival. There has been limited data on the comparison of outcomes between 1L-Osi, 1G/2G EGFR-TKIs followed by Osi and without Osi.

查看译文

关键词

osimertinib,clinical outcomes,st-line,egfr-tkis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要